226 related articles for article (PubMed ID: 3060193)
1. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
Engelhart M
Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
[TBL] [Abstract][Full Text] [Related]
2. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
3. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.
Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
Cochrane Database Syst Rev; 2000; 1998(2):CD000954. PubMed ID: 10796396
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
Arneklo-Nobin B; Elmér O; Akesson A
Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
[TBL] [Abstract][Full Text] [Related]
5. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
Dormandy JA; Berent A; Downes SJ
Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
[TBL] [Abstract][Full Text] [Related]
6. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.
Roald OK; Seem E
Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
Seibold JR; Jageneau AH
Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
[TBL] [Abstract][Full Text] [Related]
11. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
Kahan A; Amor B; Menkes CJ
Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
[TBL] [Abstract][Full Text] [Related]
12. Enalapril in Raynaud's phenomenon.
Janini SD; Scott DG; Coppock JS; Bacon PA; Kendall MJ
J Clin Pharm Ther; 1988 Apr; 13(2):145-50. PubMed ID: 2839529
[TBL] [Abstract][Full Text] [Related]
13. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
[TBL] [Abstract][Full Text] [Related]
15. International study of ketanserin in Raynaud's phenomenon.
Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL
Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807
[TBL] [Abstract][Full Text] [Related]
16. Ketanserin and capillary flow in Raynaud's phenomenon.
Tooke JE; Williams SA; Rawlinson DW; Black C
Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546
[TBL] [Abstract][Full Text] [Related]
17. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
DiGiacomo RA; Kremer JM; Shah DM
Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
[TBL] [Abstract][Full Text] [Related]
19. Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.
Baart de la Faille H; van Weelden H; Banga JD; van Kesteren RG
Arch Dermatol Res; 1986; 279(1):3-7. PubMed ID: 3545103
[TBL] [Abstract][Full Text] [Related]
20. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A
Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
